Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares saw unusually-high trading volume on Monday . Approximately 179,161 shares changed hands during trading, an increase of 160% from the previous session’s volume of 68,878 shares.The stock last traded at $3.60 and had previously closed at $3.40.

AUPH has been the topic of several recent analyst reports. HC Wainwright initiated coverage on Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They set a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. Leerink Swann reaffirmed an “outperform” rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, May 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $7.15.

The company’s market capitalization is $112.36 million. The stock has a 50 day moving average of $2.95 and a 200-day moving average of $2.68.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.